Literature DB >> 9635427

Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease.

G Casari1, M De Fusco, S Ciarmatori, M Zeviani, M Mora, P Fernandez, G De Michele, A Filla, S Cocozza, R Marconi, A Dürr, B Fontaine, A Ballabio.   

Abstract

Hereditary spastic paraplegia (HSP) is characterized by progressive weakness and spasticity of the lower limbs due to degeneration of corticospinal axons. We found that patients from a chromosome 16q24.3-linked HSP family are homozygous for a 9.5 kb deletion involving a gene encoding a novel protein, named Paraplegin. Two additional Paraplegin mutations, both resulting in a frameshift, were found in a complicated and in a pure form of HSP. Paraplegin is highly homologous to the yeast mitochondrial ATPases, AFG3, RCA1, and YME1, which have both proteolytic and chaperon-like activities at the inner mitochondrial membrane. Immunofluorescence analysis and import experiments showed that Paraplegin localizes to mitochondria. Analysis of muscle biopsies from two patients carrying Paraplegin mutations showed typical signs of mitochondrial OXPHOS defects, thus suggesting a mechanism for neurodegeneration in HSP-type disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635427     DOI: 10.1016/s0092-8674(00)81203-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  232 in total

Review 1.  Disorders related to mitochondrial membranes: pathology of the respiratory chain and neurodegeneration.

Authors:  S Di Donato
Journal:  J Inherit Metab Dis       Date:  2000-05       Impact factor: 4.982

2.  A new locus for autosomal dominant pure spastic paraplegia, on chromosome 2q24-q34.

Authors:  B Fontaine; C S Davoine; A Dürr; C Paternotte; I Feki; J Weissenbach; J Hazan; A Brice
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

Review 3.  Hereditary spastic paraparesis: a review of new developments.

Authors:  C McDermott; K White; K Bushby; P Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

Review 4.  Clinical mitochondrial genetics.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-06       Impact factor: 6.318

Review 5.  The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders.

Authors:  N Gregersen; P Bross; B S Andrese; C B Pedersen; T J Corydon; L Bolund
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

6.  Characterization of Alu and recombination-associated motifs mediating a large homozygous SPG7 gene rearrangement causing hereditary spastic paraplegia.

Authors:  Eva López; Carlos Casasnovas; Javier Giménez; Antoni Matilla-Dueñas; Ivelisse Sánchez; Víctor Volpini
Journal:  Neurogenetics       Date:  2014-11-16       Impact factor: 2.660

7.  Genetic mapping of a susceptibility locus for disc herniation and spastic paraplegia on 6q23.3-q24.1.

Authors:  M Zortea; A Vettori; C P Trevisan; S Bellini; G Vazza; M Armani; A Simonati; M L Mostacciuolo
Journal:  J Med Genet       Date:  2002-06       Impact factor: 6.318

Review 8.  Synapses and Sisyphus: life without paraplegin.

Authors:  Harris A Gelbard
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 9.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

10.  SPG7 Is an Essential and Conserved Component of the Mitochondrial Permeability Transition Pore.

Authors:  Santhanam Shanmughapriya; Sudarsan Rajan; Nicholas E Hoffman; Andrew M Higgins; Dhanendra Tomar; Neeharika Nemani; Kevin J Hines; Dylan J Smith; Akito Eguchi; Sandhya Vallem; Farah Shaikh; Maggie Cheung; Nicole J Leonard; Ryan S Stolakis; Matthew P Wolfers; Jessica Ibetti; J Kurt Chuprun; Neelakshi R Jog; Steven R Houser; Walter J Koch; John W Elrod; Muniswamy Madesh
Journal:  Mol Cell       Date:  2015-09-17       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.